Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tomás Miranda-Aquino has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In-Hospital Mortality Predictors and a Bayesian Weighted-Incidence Antibiogram in Infective Endocarditis: A Seven-Year Cohort Study from a Mexican Tertiary University Hospital

    by Itzel Elizabeth Garibay-Padilla, Jorge Eduardo Hernandez-Del Río, Dayana Estefania Orozco-Sepulveda, Christian Gonzalez-Padilla, Tomas Miranda-Aquino, Vanessa Salas-Bonales, Judith Carolina De Arcos-Jiménez, Jaime Briseño-Ramírez

    Background/Objectives: Infective endocarditis (IE) carries substantial mortality, particularly in middle-income settings where patient profiles and microbial ecology differ from those of cohorts used to derive international prognostic scores. Syndrome-specific, locally grounded decision aids for empirical therapy are also scarce. We aimed to identify predictors of in-hospital mortality, externally evaluate the RiskE and ICE scores, and construct a Bayesian weighted-incidence syndromic combination antibiogram (WISCA) for IE. Methods: We conducted a retrospective cohort study of consecutive adults with definite or possible IE admitted between January 2019 and January 2026. Candidate predictors were screened in two phases, and a clinically specified model was estimated with maximum-likelihood and Firth penalization, with 1000-replicate bootstrap optimism correction. Calibration was assessed with bootstrap calibration plots and the Hosmer–Lemeshow test. Discrimination was compared against RiskE and ICE using DeLong’s test and reclassification metrics. For empirical coverage, we built a WISCA using identified pathogens, reporting both non-Bayesian bootstrap estimates and Bayesian hierarchical partial-pooling estimates with species- and antibiotic-level random intercepts; analyses were also stratified by IE type. Results: In-hospital mortality was 22.9% in a young cohort (median 37 years) characterized by high hemodialysis prevalence (47.4%), substantial right-sided IE (46.4%), and Staphylococcus aureus predominance (32%) with no methicillin-resistant isolates. Vasopressor-requiring shock (Firth OR 9.23, 95% CI 2.40–40.61) and acute heart failure (OR 10.01, 95% CI 2.78–41.07) were the strongest predictors; the final model achieved an AUC of 0.922 (optimism-corrected 0.908), significantly outperforming RiskE (0.598) and ICE (0.632). The Bayesian WISCA identified multiple carbapenem-sparing and anti-MRSA–sparing regimens with adequate coverage (≥80%), particularly for community-acquired IE, supporting stewardship-oriented empirical selection. Coverage was consistently lower in healthcare-associated IE. Conclusions: A parsimonious three-variable model provided strong, locally valid mortality prediction in this hemodialysis-predominant, MRSA-free cohort, substantially outperforming European-derived scores. External validation in independent cohorts is required before clinical adoption. The Bayesian WISCA demonstrated that adequate empirical coverage is achievable without routine broad-spectrum agents, offering institution-specific guidance for stewardship-compatible regimen selection; multicenter validation is warranted.

  • Open Access

    In-Hospital Mortality Predictors and a Bayesian Weighted-Incidence Antibiogram in Infective Endocarditis: A Seven-Year Cohort Study from a Referral University Hospital

    by Itzel Elizabeth Garibay-Padilla, Jorge Eduardo Hernandez-Del Rio, Dayana Estefania Orozco-Sepulveda, Christian Gonzalez-Padilla, Tomas Miranda-Aquino, Vanessa Salas-Bonales, Judith Carolina De Arcos-Jimenez, Jaime Briseno-Ramirez

    Background/Objectives: Infective endocarditis (IE) carries substantial mortality, particularly in middle-income settings where patient profiles and microbial ecology differ from those of cohorts used to derive international prognostic scores. Syndrome-specific, locally grounded decision aids for empirical therapy are also scarce. We aimed to identify predictors of in-hospital mortality, externally evaluate the RiskE and ICE scores, and construct a Bayesian weighted-incidence syndromic combination antibiogram (WISCA) for IE. Methods: We conducted a retrospective cohort study of consecutive adults with definite or possible IE admitted between January 2019 and January 2026. Candidate predictors were screened in two phases and a clinically specified model was estimated with maximum-likelihood and Firth penalization, with 1000-replicate bootstrap optimism correction. Discrimination was compared against RiskE and ICE using DeLong’s test and reclassification metrics. For empirical coverage, we built a WISCA using identified pathogens, reporting both non-Bayesian bootstrap estimates and Bayesian hierarchical partial-pooling estimates with species- and antibiotic-level random intercepts; analyses were also stratified by IE type. Results: In-hospital mortality was 22.9%. Septic shock (Firth OR 9.23, 95% CI 2.40–40.61) and acute heart failure (OR 10.01, 95% CI 2.78–41.07) were the strongest independent predictors; the final model achieved an AUC of 0.922 (optimism-corrected 0.908) and outperformed RiskE (AUC 0.598) and ICE (AUC 0.632). Bayesian WISCA ranked vancomycin + gentamicin and meropenem + gentamicin highest (both 87.0%); several β-lactam–based combinations provided comparably high coverage without requiring routine carbapenems. Coverage was consistently higher for community-acquired than healthcare-associated IE. Conclusions: A simple variable model provided strong, locally valid mortality prediction and substantially outperformed international scores in this hemodialysis-predominant cohort. Bayesian WISCA offers stable, institution-specific empirical coverage estimates that can support stewardship-oriented regimen selection; multicenter validation is warranted.

  • Open Access

    Arrhythmias as Part of Long COVID Syndrome in Hospitalized Patients That Survived a Severe COVID-19 Infection and the Potential Protective Role of Metformin in These Patients

    by Haydee Ninette Morales-Vazquez, David Cardona-Müller, Fernando Grover-Paez, Carlos Gerardo Ramos-Becerra, Ernesto Germán Cardona-Muñoz, Maria Guadalupe Ramos-Zavala, Jaime Carmona-Huerta, Jorge Eduardo Hernandez-Del-Rio, Tomas Miranda-Aquino, Christian Gonzalez-Padilla, et al.

    Background: Cardiac arrhythmias are a frequent complication of acute SARS-CoV-2 infection. However, their long-term prevalence and clinical determinants among patients with post-COVID-19 syndrome, especially those previously hospitalized, remain poorly defined. Objectives: To assess the prevalence and types of arrhythmias in long COVID patients following hospitalization and to identify associated clinical risk factors. Methods: In this cross-sectional study, 53 patients previously hospitalized with confirmed COVID-19 were evaluated ≥3 months post-infection. All participants underwent a standardized clinical assessment, 12-lead electrocardiography, and 24 h Holter monitoring. Logistic and Cox regression analyses were performed to identify predictors of arrhythmia. Results: Arrhythmias were identified in 41.5% (n = 22) of patients. Atrial fibrillation (32%) was the most frequent arrhythmia, followed by sinus bradycardia (27%) and sinus tachycardia (18%). Age (OR 1.06, 95% CI 1.01–1.10, p = 0.01) and length of hospital stay (OR 1.1, 95% CI 1.01–1.2, p = 0.04) were independently associated with arrhythmia. Biguanide (metformin) therapy was inversely associated with the occurrence of arrhythmia (Exp(B) = 0.017, p = 0.008). Dyspnea (82.4%) and palpitations (41.5%) were the most commonly reported symptoms. Conclusions: Arrhythmias are common in patients with long COVID following severe disease. Advanced age and prolonged hospitalization are significant risk factors, while biguanide use may offer a protective effect. These findings underscore the need for targeted cardiac surveillance in this population.


  • Acoplamiento ventriculoarterial derecho como marcador de daño miocárdico subclínico en artritis reumatoide

    by Tomás Miranda-Aquino, Diego Alejandro Ramos-Aguas, Silvia Esmeralda Pérez-Topete, María del Socorro Cepeda-Rocha, Xochitl Citlalli Gómez-Gómez, Daniel Ochoa-Castillo, Sergio Cerpa-Cruz, Verónica González-Díaz, Christian González-Padilla, Jorge Eduardo Hernández-Del Río

  • Open Access

    Cardiopulmonary Imaging Utilization and Findings among Hospitalized COVID-19 Patients in Latin America

    by Salvador V. Spina, Marcelo L. Campos Vieira, César J. Herrera, Ana G. Munera Echeverri, Pamela Rojo, Alma S. Arrioja Salazar, Zuilma Y. Vázquez Ortiz, Roberto Baltodano Arellano, Graciela Reyes, Rocío Aceves Millán, et al.

    Describe the use and findings of cardiopulmonary imaging—chest X-ray (cX-ray), echocardiography (cEcho), chest CT (cCT), lung ultrasound (LUS), and/or cardiac magnetic resonance imaging (cMRI)—in COVID-19 hospitalizations in Latin America (LATAM). There is a lack of information on the images used and their findings during the SARS-CoV-2 pandemic in LATAM. Multicenter, prospective, observational study of COVID-19 inpatients, conducted from March to December 2020, from 12 high-complexity centers, in nine LATAM countries. Adults (>18 years) with at least one imaging modality performed, followed from admission until discharge and/or in-hospital death, were included. We studied 1,435 hospitalized patients (64% males) with a median age of 58 years classified into three regions: Mexico (Mx), 262; Central America and Caribbean (CAC), 428; and South America (SAm), 745. More frequent comorbidities were overweight/obesity, hypertension, and diabetes. During hospitalization, 58% were admitted to the ICU. The in-hospital mortality was 28%, and it was highest in Mx (37%). The most frequent images performed were cCT (61%), mostly in Mx and SAm, and cX-ray (46%), significant in CAC. The cEcho was carried out in 18%, similarly among regions, and LUS was carried out in 7%, with a higher frequently in Mx. Abnormal findings on the cX-ray were peripheral or basal infiltrates, and in cCT abnormal findings were the ground glass infiltrates, more commonly in Mx. In LUS, interstitial syndrome was the most abnormal finding, predominantly in Mx and CAC. Renal failure was the most prevalent complication (20%), predominant in Mx and SAm. Heart failure developed in 13%, predominant in Mx and CAC. Lung thromboembolism was higher in Mx while myocardial infarction was in CAC. Logistic regression showed associations of abnormal imaging findings and their severity, with comorbidities, complications, and evolution. The use and findings of cardiopulmonary imaging in LATAM varied between regions and had a great impact on diagnosis and prognosis.


  • Strain de aurícula izquierda triplanar

    by Michel Machuca-Hernández, Tomás Miranda-Aquino, María Cepeda-Rocha, Sergio Herrera-Méndez, Jorge Eduardo Hernández-Del Río

  • Open Access

    Echocardiographic parameters as predictors of three-months mortality in patients with 2019 Coronavirus infection

    by T Miranda Aquino, J M Pereira-Forcado, B Ordonez-Salazar, G Dominguez-Trejo, A Rangel-Guerra, J Martinez-Castillo, R J Vazquez-Orozco, A P Guevara-Canseco, S E Perez-Topete, R Aceves-Millan, et al.

    Background: Coronavirus disease 2019 is a systemic entity, where cardiac involvement has been described. The echocardiogram is a diagnostic tool that describes myocardial damage with good certainty. Objectives: Determine which echocardiographic parameters are predictors of mortality. Analyze if there is a difference in clinical, laboratory and echocardiographic variables in terms of patients who died versus those who survived. Investigate the cut-off point of the echocardiographic parameters that is best associated with mortality. Methods: Prospective, analytical, comparative study. Patients admitted to the hospital with Coronavirus 2019 infection. Clinical, laboratory and echocardiographic variables will be assessed. The association with three-month mortality of the different variables will be determined. We used ROC-curves for the best cut-off associated with mortality. The association with three-month mortality was analized using Cox regression, unadjusted analysis of the variables was performed, as well as adjusted analysis for age and gender. Results: 84 patients were included, a mortality of 29% was documented. Significant differences were found in the left atrial volumen index, the E/e', the proportion of dilatation of the right ventricle and diastolic dysfunction. Tricuspid annulus anterior systolic excursion (TAPSE), pulmonary artery acceleration time (PAA), tricuspid regurgitation velocity (TRV), pulmonary artery systolic pressure (PASP), left ventricular longitudinal strain (LVGLS), of the left atrium (LAGLS) and the right ventricular free wall longitudinal strain (RVFWLS). Right ventricular dilation, right ventricular shortening fraction, TAPSE, PASP, TRV, LVGLS, LAGLS, and RVFWLS were associated with mortality. Conclusion: Right ventricular dilation, right ventricular shortening fraction, TAPSE, PASP, TRV, LVGLS, LAGLS, and RVFWLS are the echocardiographic parameters that were associated with three-month mortality. Funding Acknowledgement: Type of funding sources: None. Table 2

  • Hiperuricemia asintomática y enfermedad arterial coronaria

    by Tomás Miranda-Aquino, Silvia Esmeralda Pérez-Topete, Christian González-Padilla, Jorge Eduardo Hernández-Del Río, Óscar Sergio Lomelí-Sánchez, Ramón Miguel Esturau-Santaló, Sergio Ramón Gutiérrez-Ureña, Verónica González-Díaz


  • Deformación miocárdica de la aurícula izquierda en pacientes con lupus eritematoso sistémico

    by Silvia Esmeralda Pérez-Topete, Tomás Miranda-Aquino, Jorge Eduardo Hernández-Del Río, Sergio Cerpa-Cruz, Sergio Ramón Gutiérrez-Ureña, Gloria Martínez-Bonilla, Verónica González-Díaz